ESMO 2012 Conference

Platinum-Resistant Ovarian Cancer: Bevacizumab Improves Survival When Added to Chemotherapy

Phoebe Starr

November 2012, Vol 3, No 8 - ESMO 2012 Conference

?Vienna, Austria—Adding bevacizumab (Avastin) to chemotherapy im­proves outcomes in patients with platinum-resistant recurrent ovarian cancer, according to results of the phase 3 clinical trial AURELIA, which was presented at the 2012 European Society for Medical Oncology Congress. Bevacizumab im­proved progression-free survival (PFS) and overall response rate (ORR) with any of the 3 chemotherapy regimens in the study, but adding bevacizumab to weekly paclitaxel was the most active combination in an exploratory analysis of the trial.

[ Read More ]

Head-to-Head Comparison: Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Caroline Helwick

October 2012, Vol 3, No 7 - ESMO 2012 Conference

Vienna, Austria—In a head-to-head comparison of 2 treatments for meta­static renal-cell carcinoma (mRCC), pazopanib (Votrient) showed similar efficacy to sunitinib (Sutent), with a 1-month survival advantage for sunitinib, which was associated with fewer side effects and an increased quality of life (QOL), suggested Robert J. Motzer, MD, Professor of Medicine, Weill Medical College of Cornell University, and an attending physician at Memorial Sloan-Kettering Cancer Center, New York. [ Read More ]

Updated Data Confirm Survival Benefits with T-DM1 in Breast Cancer and with Regorafenib in Colon Cancer

Phoebe Starr

October 2012, Vol 3, No 7 - ESMO 2012 Conference

Vienna, Austria—The updated analyses of 2 major studies of drugs that were recently approved by the US Food and Drug Administration (FDA) confirm the benefits of tras­tuzumab emtansine (T-DM1) in patients with advanced HER2-positive breast cancer and of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC). Both studies were presented at the 2012 European Society for Medical On­cology (ESMO) Congress. Regora­fenib was approved by the FDA for the treatment of mCRC during the ESMO meeting (see article here).

[ Read More ]

Crizotinib Superior to Chemotherapy, Extends Median Survival in First Head-to-Head Trial

Audrey Andrews

October 2012, Vol 3, No 7 - ESMO 2012 Conference

Vienna, Austria—In the first head-to-head phase 3 clinical trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) proved more effective than standard chemotherapy with pemetrexed (Alimta) or docetaxel (Taxotere) as a second-line treatment for patients with non–small-cell lung cancer (NSCLC) and the ALK genetic abnormality.

[ Read More ]